公开(公告)号：EP2958953A1

公开(公告)日：2015-12-30

申请号：EP14713178.3

申请日：2014-02-25

申请人： Arkema France ,  Centre National de la Recherche Scientifique (CNRS) ,  Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris

发明人： LEIBLER, Ludwik ,  TOURNILHAC, François ,  CAPELOT, Mathieu ,  AGNAOU, Réda ,  PINEAU, Quentin

IPC分类号： C08G69/34 ,  C08G69/48 ,  C08L101/02

CPC分类号： C07D233/36 ,  C08G83/008

摘要： The present invention relates to novel supramolecular materials made of straight or branched oligoamides, terminated at each of the ends thereof by an associative group including a nitrogen heterocycle supported by a specific sequence. The invention also relates to the method for preparing said materials, as well as to the uses thereof.

公开(公告)号：EP2621901B1

公开(公告)日：2015-07-29

申请号：EP11767355.8

申请日：2011-09-27

申请人： Radius Health, Inc

发明人： MILLER, Chris, P.

IPC分类号： C07D207/26 ,  C07D233/36 ,  C07D263/24 ,  C07D417/04 ,  A61K31/402 ,  A61K31/4166 ,  A61K31/421 ,  A61P19/10

CPC分类号： C07D417/10 ,  C07D207/26 ,  C07D233/36 ,  C07D263/24 ,  C07D417/04 ,  G01N33/74 ,  G01N2333/70567

公开(公告)号：EP2805937A1

公开(公告)日：2014-11-26

申请号：EP14173061.4

申请日：2008-08-20

申请人： AstraZeneca AB

发明人： Arnold, James ,  Edwards, Phil ,  Griffin, Andrew ,  Groblewski, Thierry ,  Labrecque, Denis ,  Throner, Scott ,  Wesolowski, Steven ,  Brugel, Todd Andrew ,  Brown, Dean

IPC分类号： C07D211/40 ,  C07D207/12 ,  C07D295/18 ,  C07D231/12 ,  C07D233/36 ,  C07D239/26 ,  C07D243/08 ,  A61K31/495 ,  A61P25/00

CPC分类号： A61K31/496 ,  A61K31/495 ,  A61K31/551 ,  C07D207/12 ,  C07D207/27 ,  C07D211/40 ,  C07D211/76 ,  C07D213/56 ,  C07D231/12 ,  C07D233/36 ,  C07D239/26 ,  C07D243/08 ,  C07D295/18 ,  C07D295/182 ,  C07D295/185

摘要： Disclosed herein is at least one cyclopropyl amide derivative of formula I, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative of formula I disclosed herein, and at least one method of using at least one cyclopropyl amide derivative of formula I disclosed herein, for treating at least one histamine H3 receptor associated condition therewith.

摘要翻译： 本文公开了至少一种式I的环丙基酰胺衍生物，至少一种药物组合物，其包含至少一种本文公开的式I的环丙基酰胺衍生物和至少一种使用至少一种本文公开的式I的环丙基酰胺衍生物的方法， 用于治疗至少一种与组胺H3受体相关的病症。

公开(公告)号：EP2593485A1

公开(公告)日：2013-05-22

申请号：EP11730680.3

申请日：2011-07-12

申请人： Compagnie Générale des Etablissements Michelin ,  MICHELIN Recherche et Technique S.A.

发明人： ARAUJO, José ,  FAVROT, Jean-Michel ,  SALIT, Anne-Frédérique ,  SEEBOTH, Nicolas

IPC分类号： C08C19/28 ,  C08F8/30 ,  C08F10/06

CPC分类号： C08C19/22 ,  C07D233/34 ,  C07D233/36 ,  C08C19/28 ,  C08F8/30 ,  C08F36/04

摘要： The present invention relates to a modified polymer produced by grafting a compound thereto, said compound including at least one group Q and at least one group A bonded together by at least one, and preferably only one, spacer group Sp, where: Q includes a dipole containing at least one, and preferably only one, nitrogen atom capable of being grafted onto the polymer chain by [l,3]-dipolar cycloaddition; A includes a combined group that includes at least one nitrogen atom; and Sp is an atom or a group of atoms forming a bond between Q and A.

公开(公告)号：EP2523940A1

公开(公告)日：2012-11-21

申请号：EP11704265.5

申请日：2011-01-07

申请人： Arkema France

发明人： BALOCHE, Alain ,  GAMET, Jean-Paul ,  GILLET, Jean-Philippe

IPC分类号： C07D233/36 ,  C07D233/42

CPC分类号： C07D233/36 ,  C07D233/42

摘要： The present invention relates to a method for preparing 1-(2-aminoethyl)imidazolidin-2-one or the thiocarbonyl thereof, and also to the product that can be obtained according to this method, and which has a purity of at least 98%, and to the uses thereof.

公开(公告)号：EP1874733B1

公开(公告)日：2012-06-20

申请号：EP06742597.5

申请日：2006-04-18

申请人： Grünenthal GmbH

发明人： FRANK, Robert ,  SUNDERMANN, Bernd ,  SCHICK, Hans ,  SONNENSCHEIN, Helmut

IPC分类号： C07D233/36 ,  C07D233/42 ,  A61K31/4166 ,  C07D235/26 ,  C07D235/28 ,  A61K31/4184 ,  C07D239/10 ,  A61K31/513

CPC分类号： C07D239/10 ,  C07D233/36 ,  C07D233/42 ,  C07D235/26 ,  C07D235/28

摘要： The invention relates to substituted cyclic urea derivatives, wherein X represents O, S or N-C=N; m is 1 or 2; n is 1 or 2; p1 and p2 represent independently 0, 1, 2 or 3, and the sum of p1 and p2 is 0, 1, 2 or 3. The invention also relates to methods for producing said derivatives, to drugs containing these compounds and to the use of these compounds for producing drugs. The inventive drugs are especially useful for vanilloid receptor 1 (VR1/TRPV1) regulation, preferably for vanilloid receptor 1 (VR1/TRPV1) inhibition and/or vanilloid receptor 1 (VR1/TRPV1) stimulation.

公开(公告)号：EP2004601B1

公开(公告)日：2011-03-02

申请号：EP07734152.7

申请日：2007-03-30

申请人： Matrix Laboratories Limited

发明人： GOPALAN, Balasubramanian ,  RAVI, Dhamjewar ,  RASHEED, Mohammed ,  SREEDHARA, Swamy, Keshavapura, Hosamane ,  ISHTIYAQUE, Ahmad

IPC分类号： C07D207/16 ,  C07D207/26 ,  C07D207/32 ,  C07D209/48 ,  C07D233/36 ,  C07D249/08 ,  C07D257/04 ,  C07D271/06 ,  C07D275/02 ,  C07D277/34 ,  C07D295/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/4196

CPC分类号： C07D249/08 ,  C07D207/16 ,  C07D207/27 ,  C07D207/323 ,  C07D209/48 ,  C07D233/36 ,  C07D257/04 ,  C07D271/06 ,  C07D275/02 ,  C07D277/34 ,  C07D295/13 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.

公开(公告)号：EP2004601A1

公开(公告)日：2008-12-24

申请号：EP07734152.7

申请日：2007-03-30

申请人： Matrix Laboratories Limited

发明人： GOPALAN, Balasubramanian ,  RAVI, Dhamjewar ,  RASHEED, Mohammed ,  SREEDHARA, Swamy, Keshavapura, Hosamane ,  ISHTIYAQUE, Ahmad

IPC分类号： C07D207/16 ,  C07D207/26 ,  C07D207/32 ,  C07D209/48 ,  C07D233/36 ,  C07D249/08 ,  C07D257/04 ,  C07D271/06 ,  C07D275/02 ,  C07D277/34 ,  C07D295/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/4196

CPC分类号： C07D249/08 ,  C07D207/16 ,  C07D207/27 ,  C07D207/323 ,  C07D209/48 ,  C07D233/36 ,  C07D257/04 ,  C07D271/06 ,  C07D275/02 ,  C07D277/34 ,  C07D295/13 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.

公开(公告)号：EP1864971A1

公开(公告)日：2007-12-12

申请号：EP06731350.2

申请日：2006-03-31

申请人： Takeda Pharmaceutical Company Limited

发明人： CHO, Nobuo c/o TAKEDA PHARMACEUTICAL CO. Ltd. ,  KASAI, Shizuo c/o TAKEDA PHARMACEUTICAL CO. Ltd. ,  YAMASHITA, Toshiro c/o TAKEDA PHARMACEUT.CO. Ltd.

IPC分类号： C07D207/26 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/451 ,  A61K31/454 ,  A61K31/496 ,  A61K31/505 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/695 ,  A61P1/04 ,  A61P1/06 ,  A61P1/12

CPC分类号： C07F7/1856 ,  C07D207/26 ,  C07D207/50 ,  C07D211/76 ,  C07D223/10 ,  C07D233/34 ,  C07D233/36 ,  C07D235/26 ,  C07D239/10 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D409/04 ,  C07D409/10 ,  C07D413/10 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1):

wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

摘要翻译： 本发明涉及包含由式（1）表示的化合物的11 2-羟基类固醇脱氢酶抑制剂：其中每个符号如说明书中所定义，或其盐或其前药。 本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，作为预防或治疗糖尿病，胰岛素抵抗，肥胖，脂质代谢异常，高血压等药物， 喜欢。

公开(公告)号：EP1847530A1

公开(公告)日：2007-10-24

申请号：EP06712670.6

申请日：2006-01-31

申请人： KYOWA HAKKO KOGYO CO., LTD.

发明人： SASHO, Setsuya c/o BioFrontier Laboratories ,  SEISHI, Takashi c/o Head Office,KYOWA HAKKO KOGYO CO., LTD., ,  ATSUMI, Eri ,  OSAKADA, Mariko ,  HIROSE, Ryo c/o Head Office, KYOWA HAKKO KOGYO CO., LTD., ,  TOKI, Shinichiro c/o Head Office, ,  TSUKII, Katsuyoshi ,  SHIRAKURA, Shiro

IPC分类号： C07D211/58 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61P1/04 ,  A61P3/04 ,  A61P9/00 ,  A61P9/12 ,  A61P25/04

CPC分类号： C07D295/13 ,  C07D211/26 ,  C07D211/58 ,  C07D233/20 ,  C07D233/26 ,  C07D233/36 ,  C07D233/48 ,  C07D233/52 ,  C07D235/16 ,  C07D239/06 ,  C07D295/145 ,  C07D401/06 ,  C07D401/14 ,  C07D417/06

摘要： The present invention provides a diamine derivative or the like represented by the general formula (I):

{wherein Q represents an oxygen atom or the like, R G represents a hydrogen atom or the like, R I represents

(wherein p and r may be the same or different, and each represents 0 or the like, R A represents a hydrogen atom or the like, and R B and R c may be the same or different, and each represents a hydrogen atom or the like), R H represents a hydrogen atom or the like, and R J represents:

(wherein q and s may be the same or different, and each represents 0 or the like, R D represents a hydrogen atom or the like, and R E and R F may be the same or different, and each represents a hydrogen atom or the like) or the like}, etc.

摘要翻译： 本发明提供由通式（I）表示的二胺衍生物等：{其中Q表示氧原子等，RG表示氢原子等，RI表示（其中p和r可以相同） 或者不同，各自表示0等，RA表示氢原子等，RB和R c可以相同或不同，表示氢原子等），RH表示氢原子或 并且RJ表示：（其中q和s可以相同或不同，并且各自表示0等，RD表示氢原子等，RE和RF可以相同或不同，并且各自表示 氢原子等）等}等